International Journal of Clinical Oncology最新文献

{"title":"Clinical usefulness of nutritional and immunological indices to distinguish gallbladder carcinoma from benign disease.","authors":"Daisuke Ogawa, Hiromitsu Hayashi, Shinsei Yumoto, Rumi Itoyama, Yuki Kitano, Shigeki Nakagawa, Hirohisa Okabe, Masaaki Iwatsuki","doi":"10.1007/s10147-025-02764-8","DOIUrl":"10.1007/s10147-025-02764-8","url":null,"abstract":"<p><strong>Background: </strong>It is challenging to accurately and preoperatively diagnose gallbladder carcinoma (GBC) because patients are often asymptomatic or present with nonspecific symptoms that mimic common benign diseases in radiological findings. In this study, we evaluated the clinical usefulness of nutritional and immunological indices to distinguish GBC from benign disease.</p><p><strong>Methods: </strong>This study included 113 patients who underwent surgical resection for suspected GBC (37 benign and 76 GBC cases by pathological diagnosis). As the nutritional and immunological indices, the geriatric nutritional risk index (GNRI), modified Glasgow prognostic score (mGPS), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and prognostic nutrition index (PNI) were examined, and their usefulness in distinguishing GBC from benign disease was determined using logistic regression analyses.</p><p><strong>Results: </strong>GBC cases displayed significantly worse nutritional and immunological status in the GNRI, mGPS, NLR, PLR, and PNI compared with those of the benign cases. As the predictive factors to distinguish GBC from benign disease, age > 75 years, GNRI < 101.7, and PLR ≥ 1.76 were identified by multivariate logistic regression analyses.</p><p><strong>Conclusion: </strong>Patients with GBC showed poor nutritional or immunological status compared with patients with benign disease, and a low GNRI and high PLR may be noninvasive predictors of GBC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1386-1397"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of capecitabine plus temozolomide combination therapy in patients with advanced or metastatic pancreatic neuroendocrine tumors: a retrospective observational single-center study.","authors":"Yukiko Hibino, Susumu Hijioka, Chigusa Morizane, Daiki Agarie, Kohei Okamoto, Daiki Yamashige, Shin Yagi, Soma Fukuda, Masaru Kuwada, Yasuhiro Komori, Mao Okada, Yuta Maruki, Yoshikuni Nagashio, Hideki Ueno, Takuji Okusaka","doi":"10.1007/s10147-025-02779-1","DOIUrl":"10.1007/s10147-025-02779-1","url":null,"abstract":"<p><strong>Background: </strong>Treatment strategies for patients with unresectable or recurrent pancreatic neuroendocrine tumors (pNETs) have been investigated, and combination therapy with capecitabine plus temozolomide (CAPTEM) has demonstrated favorable outcomes. In response to these results, the CAPTEM regimen has been widely used in several countries, including Western nations. However, it is yet to be approved in Japan, and its efficacy and safety in the Japanese population remain unclear. In the present study, we examined the efficacy and safety of CAPTEM in Japanese patients with unresectable or recurrent pNETs.</p><p><strong>Methods: </strong>Data were retrospectively collected from the medical records of the National Cancer Center Hospital.</p><p><strong>Results: </strong>Fifteen patients with pNETs had received CAPTEM therapy, and 47% of the patients had WHO Grade 2 disease and 47% had WHO Grade 3 disease. The objective response rates and disease control rates were 26.7 and 66.7%, respectively. The median observation period was 20.8 months. The median progression-free survival was 5.3 months (95% confidence interval [CI]: 0.9-NA), and 1-year survival rate was 81.2% (95% CI: 41.5-95.2%). The most common adverse events (AEs) associated with CAPTEM therapy were hematologic and gastrointestinal toxicities. One patient experienced CTCAE grade 3 neutropenia, but no AE-related deaths were observed.</p><p><strong>Conclusions: </strong>This is the first study conducted to demonstrate CAPTEM is a valuable regimen also in the Japanese population, consistent with its established efficacy outside Japan. As reported previously, CAPTEM therapy was associated with high disease control rates, and it could be a valuable regimen in the Japanese population.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1409-1416"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD155 expression and co-expression with PD-L1 are not associated with poor prognosis in patients with stage II and III lung adenocarcinoma undergoing surgical resection.","authors":"Kyoto Matsudo, Kazuki Takada, Asato Hashinokuchi, Taichi Nagano, Fumihiko Kinoshita, Takaki Akamine, Mikihiro Kohno, Tomoyoshi Takenaka, Mototsugu Shimokawa, Yoshinao Oda, Tomoharu Yoshizumi","doi":"10.1007/s10147-025-02771-9","DOIUrl":"10.1007/s10147-025-02771-9","url":null,"abstract":"<p><strong>Background: </strong>CD155 has been identified as a ligand for T-cell immunoreceptor with Ig and ITIM domains. Herein, we investigated the relationship between the expressions of CD155 and programmed cell death-ligand 1 (PD-L1) and clinical outcomes in patients with surgically resected lung adenocarcinoma.</p><p><strong>Methods: </strong>This study included 426 patients diagnosed with pathological stage (pStage) I-III lung adenocarcinoma who underwent surgery at Kyushu University Hospital. The number of tumor cells expressing CD155 and PD-L1 was assessed by immunohistochemistry, and the clinical significance of CD155 expression and CD155/PD-L1 co-expression in prognosis was investigated.</p><p><strong>Results: </strong>Among the enrolled cohort, 320 (75.1%), 60 (14.1%), and 46 (10.8%) patients were diagnosed with pStage I, II, and III, respectively. Tissues from 112 patients (26.3%) were classified as having high CD155 expression. Co-expression of CD155 and PD-L1 was observed in 44 patients (10.3%). The High CD155 and CD155/PD-L1 co-expression groups had significantly poorer prognosis in pStage I-III lung adenocarcinoma. However, subgroup analysis revealed that the clinical significance of both CD155 expression and CD155/PD-L1 co-expression differed widely between patients with pStage I and II-III. Multivariate Cox proportional hazards regression analyses showed that high CD155 expression and CD155/PD-L1 co-expression were not independent poor prognostic factors in pStage II-III lung adenocarcinoma.</p><p><strong>Conclusion: </strong>Our findings suggest that neither CD155 expression or CD155/PD-L1 co-expression are associated with poor prognosis in pStage II-III lung adenocarcinoma.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1319-1330"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of obesity on the outcomes and cost of robotic surgery for Stage IA endometrial cancer: a regional perspective from Japan.","authors":"Mika Mizuno, Shinichi Togami, Mai Nakazono, Yuriko Higashi, Nozomi Furuzono, Mika Fukuda, Hiroaki Kobayashi","doi":"10.1007/s10147-025-02772-8","DOIUrl":"10.1007/s10147-025-02772-8","url":null,"abstract":"<p><strong>Background: </strong>The incidence of endometrial cancer in Japan has more than doubled over the past 2 decades because of increasing obesity rates and the unique physiological traits of Asian populations. The aim of this retrospective study was to examine the impact of obesity on surgical outcomes, prognosis, and costs.</p><p><strong>Methods: </strong>A total of 197 patients with stage IA endometrial cancer who underwent robot-assisted hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy/biopsy from 2018 onward were included. Patients were divided into the BMI < 30 kg/m² group (n = 117) and the BMI ≥ 30 kg/m² group (n = 80). The clinical and pathological factors, surgical outcomes, perioperative complications, and treatment costs were compared. The median follow-up period was 34.9 months (range: 6.1-84.2).</p><p><strong>Results: </strong>In the BMI ≥ 30 kg/m² group, significant differences in comorbidities, including diabetes mellitus (19.7% vs. 51.3%), hypertension (43.6% vs. 58.8%), and hyperlipidemia (29.9% vs. 50%), were detected. However, no significant differences were found in operative time, blood loss volume, perioperative complication rates, or 5-year cancer-specific survival rates (97.6% vs. 100%). Surgical and hospitalization costs were higher in the BMI ≥ 30 kg/m² group, indicating a financial burden for both patients and healthcare facilities. Additionally, a higher prevalence of newly developed lifestyle-related diseases, such as cardiovascular diseases and diabetes, was observed during the follow-up (2.5% vs. 10%).</p><p><strong>Conclusions: </strong>While obesity (BMI ≥ 30) did not significantly impact surgical outcomes or cancer prognoses, it did increase treatment costs and the risk of lifestyle-related diseases. Thus, preventive strategies, including lifestyle counseling, are needed to reduce obesity-related health burdens.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1426-1435"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distant parenchymal recurrence during long-term use of TTFields treatment for glioblastoma.","authors":"Yuhei Takido, Fumiharu Ohka, Shoichi Deguchi, Kazuya Motomura, Koichi Mitsuya, Kosuke Aoki, Yoshiki Shiba, Kazuhito Takeuchi, Yuichi Nagata, Junya Yamaguchi, Yuji Kibe, Yutaro Fuse, Sachi Maeda, Hiroki Shimizu, Ryuta Saito","doi":"10.1007/s10147-025-02775-5","DOIUrl":"10.1007/s10147-025-02775-5","url":null,"abstract":"<p><strong>Background: </strong>Tumor treating fields (TTFields) treatment has been an important option for the treatment of glioblastoma. The introduction of novel treatment options may lead to distinct recurrence patterns compared to those observed with conventional therapies; however, the specific recurrence pattern during TTFields treatment has not been elucidated.</p><p><strong>Methods and results: </strong>Here, we analyzed 39 cases of glioblastoma treated with TTFields. Although a usage rate of more than 75% is recommended, among 39 cases, 18 discontinued TTFields treatment owing to requests by patients with lower usage rates. In these discontinued cases, patients exhibiting sensory aphasia were more frequently included compared to those who continued TTFields (44.4%, p < 0.001). Among 21 cases involving patients who continued TTFields, tumor recurrence was observed in 15 of those cases. Five out of 15 cases (33.3%) exhibited recurrence in distant parenchyma from the primary lesion. A higher usage rate and relatively longer use of TTFields were observed in these five cases, along with more favorable progression-free survival than those in the other 10 cases (p = 0.019, p = 0.040, and p = 0.024, respectively). In one case, recurrent tumors with lower grade glioma histology but molecular markers characteristic for glioblastoma, IDH-wildtype were indentified. This tumor arose in an area that received a lower local minimum power density of TTFields compared to the primary lesion, following long-term TTFields therapy.</p><p><strong>Conclusions: </strong>Long-term use of TTFields might be correlated with a high frequency of distant parenchymal recurrence in cases with favorable response.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1309-1318"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy.","authors":"Kiichiro Ninomiya, Satoru Miura, Yuko Oya, Tomohiro Sakamoto, Kentaro Tanaka, Shunsuke Teraoka, Masahiro Morise, Satoshi Morita","doi":"10.1007/s10147-025-02774-6","DOIUrl":"10.1007/s10147-025-02774-6","url":null,"abstract":"<p><p>The results of subgroup analyses of clinical trials are important reference information when considering the generalizability of a study treatment, i.e., providing the best treatment for each individual patient. The results of subgroup analyses are often presented in publications, etc. as forest plots focusing on patient backgrounds. However, it is important to fully understand and grasp some of the issues involved in subgroup analyses and to interpret the results carefully to apply them in clinical practice. Although the literature includes some reports on how subgroup analyses should be evaluated and handled for the purpose of establishing medical practice guidelines, most of the papers have mainly evaluated the reliability of subgroup analyses from a statistical perspective; few of them have incorporated clinical importance in their evaluations. Therefore, in December 2019, we established a Subgroup Analysis Review Committee consisting of oncologists specializing in lung cancer treatment and statistical experts among the members of the Guidelines Review Committee of the Japanese Lung Cancer Association, with the aim of appropriately reflecting subgroup analysis in Japanese lung cancer practice guidelines. We developed a new evaluation strategy to incorporate clinical aspects as well as reliability assessment. Specifically, on the basis of a clinical and statistical review of the problems with subgroup analyses presented as clinical trial results, we developed criteria and procedures to ensure consistency and fairness in the citation of clinical guidelines.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1259-1267"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidance on the short hydration method for cisplatin administration.","authors":"Kiichiro Ninomiya, Kei Kunimasa, Yasuko Kurata, Yuki Sato, Yasuhito Fujisaka, Hitoshi Ishikawa, Katsuyuki Hotta","doi":"10.1007/s10147-025-02780-8","DOIUrl":"10.1007/s10147-025-02780-8","url":null,"abstract":"<p><p>Cisplatin is currently used as the central agent in several cancer chemotherapy protocols because of its broad antitumor spectrum and potent antitumor effects; however, preventing cisplatin-induced renal damage and other adverse events is challenging. Recently, several clinical studies have shown that a short hydration method could prevent cisplatin-induced renal damage. In addition, appropriate magnesium supplementation and administration of forced diuretics have been shown to be renoprotective. The Japanese Lung Cancer Society Guidelines Committee has summarized the evidence of renal protection regarding cisplatin administration to provide optimal administration guidance for the cisplatin short hydration method.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1287-1293"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of preoperative mean corpuscular volume in patients with stage II/III colorectal cancer and anemia.","authors":"Shuhei Asai, Hideo Miyake, Hidemasa Nagai, Yuichiro Yoshioka, Koji Shibata, Junichi Takamizawa, Norihiro Yuasa","doi":"10.1007/s10147-025-02765-7","DOIUrl":"10.1007/s10147-025-02765-7","url":null,"abstract":"<p><strong>Background: </strong>Several studies have examined the relationship between mean corpuscular volume (MCV) and prognosis of patients with colorectal cancer (CRC); however, these findings have been inconsistent. This study aimed to investigate the association between the preoperative MCV and recurrence-free survival (RFS) in patients with CRC.</p><p><strong>Methods: </strong>We analyzed 1876 patients with stage II/III CRC who underwent R0 resection. The relationships between clinicopathological factors and RFS were investigated using univariate and multivariate analyses. The prognostic significance of the MCV was examined in various clinicopathological contexts. Anemia was defined as Hb < 13 g/dL in men and Hb < 12 g/dL in women.</p><p><strong>Results: </strong>The mean patient age was 69 ± 11 years. The 5-year RFS rate was 73.3%. Multivariate analysis showed that tumor location, histological grade, stage, serum carcinoembryonic antigen level, carbohydrate antigen 19-9, neutrophil/lymphocyte ratio, and MCV were significant independent risk factors for RFS. Hazard ratios for recurrence were 0.60 for MCV < 80 fL and 1.76 for MCV ≥ 100 fL, compared to MCV 80-100 fL (p < 0.033). The 5-year RFS rates were 83.4% and 58.9%, respectively. This trend was more pronounced in patients with anemia and was contradictory in those without anemia.</p><p><strong>Conclusion: </strong>MCV < 80 fL and ≥ 100 fL can be an indicator of favorable and worse RFS, respectively, in patients with stage II/III CRC and anemia.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1365-1375"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan.","authors":"Yusa Togashi, Masayuki Nagahashi, Aoi Oshiro, Gen Sugimoto, Ayumu Mitsuyoshi, Haruka Kanaoka, Akira Hattori, Junko Tsuchida, Tomoko Higuchi, Arisa Nishimukai, Yasuo Miyoshi","doi":"10.1007/s10147-025-02768-4","DOIUrl":"10.1007/s10147-025-02768-4","url":null,"abstract":"<p><strong>Background: </strong>Development of antibody-drug conjugates, including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), has improved the outcomes of patients with HER2-positive breast cancer. We compared the association between peripheral blood biomarkers and outcomes in patients with breast cancer treated with T-DM1 and T-DXd.</p><p><strong>Methods: </strong>Eighty-five women treated with T-DM1 (n = 40) or T-DXd (n = 45) for advanced disease were evaluated. Overall survival (OS) and OS after the end of treatment (EOT) were compared based on changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) between baseline and EOT.</p><p><strong>Results: </strong>In the T-DM1 group, patients with a low NLR at EOT had significantly longer OS after EOT than those with a high NLR (p = 0.007), and patients with a high ALC at EOT had longer OS after EOT (p = 0.071). In the T-DXd group, the ALC and NLR were not associated with OS. The exploratory subgroup analysis suggested that patients with high ALC at EOT had better OS after EOT (p = 0.038) in the T-DXd (HER2-low) group (n = 19), whereas ALC and NLR were not associated with the outcome in the T-DXd (HER2-positive) group (n = 26). Multivariable analysis revealed that the NLR at EOT was an independent prognostic factor for OS after EOT, after adjusting for clinicopathological factors, in the T-DM1 group (p = 0.019).</p><p><strong>Conclusion: </strong>Immune status may influence treatment outcomes in the T-DM1 and T-DXd (HER2-low) groups. Conversely, in the T-DXd (HER2-positive) group, the treatment outcome was independent of immune status.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1331-1340"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized prognostic model for colorectal cancer in the era of precision medicine: a dynamic approach based on real-world data.","authors":"Keisuke Okura, Keita Fukuyama, Satoru Seo, Hiroto Nishino, Tomoaki Yoh, Norihiro Shimoike, Takahiro Nishio, Yukinori Koyama, Satoshi Ogiso, Takamichi Ishii, Koya Hida, Shigemi Matsumoto, Manabu Muto, Satoshi Morita, Kazutaka Obama, Etsuro Hatano","doi":"10.1007/s10147-025-02766-6","DOIUrl":"10.1007/s10147-025-02766-6","url":null,"abstract":"<p><strong>Background: </strong>Predicting individual prognosis is required for patients with colorectal cancer in the era of precision medicine. However, this may be challenging for the conventional survival analysis such as the Cox proportional hazards model. This study aims to develop a personalized prognostic prediction that incorporates longitudinal data to improve predictions for colorectal cancer patients.</p><p><strong>Methods: </strong>Patients with advanced or recurrent colorectal cancer, who received treatment at Kyoto University Hospital between April 2015 and December 2021, were retrospectively analyzed. The Joint model is one of the dynamic prediction models. Using longitudinal clinical data, a carcinoembryonic antigen (CEA) prediction equation was developed for each patient. Additionally, a personalized prognostic prediction model was created using the Joint model. The prediction accuracy of the Joint model was compared with one of the Cox proportional hazards model.</p><p><strong>Results: </strong>Among the 1010 patients, 614 patients were enrolled. The median frequency of tumor marker measurement (per patient) was 20 times (range: 3-117 times). CEA values could be predicted accurately and the Pearson's correlation coefficient between measured CEA and predicted CEA was 0.931. In the Joint model, the significant prognostic factors were baseline age (HR, 1.039; 95% CI, 1.025-1.054), poor-differentiated tumor (HR, 2.600; 95% CI 1.446-4.675) and log₂ (predicted CEA) (HR, 1.551; 95% CI 1.488-1.617). The areas under the curve at 2, 3, 4, and 5 were significantly higher for the Joint model than for the Cox proportional hazards model, respectively.</p><p><strong>Conclusion: </strong>The Joint model may accurately predict personalized prognosis that reflects changes in longitudinal tumor marker values.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1376-1385"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}